Accumulating evidence has indicated that noncoding RNAs (ncRNAs) are involved in doxorubicin-induced cardiotoxicity (DIC). However, the ncRNA-associated competing endogenous RNA (ceRNA)-mediated regulatory mechanisms in DIC remain unclear. In this study, we aimed to systematically investigate the alterations in expression levels of long noncoding RNA (lncRNA), circular RNA (circRNA), microRNA (miRNA), and mRNA in a DIC mouse model through deep RNA sequencing (RNA-seq). The results showed that 217 lncRNAs, 41 circRNAs, 11 miRNAs and 3633 mRNAs were aberrantly expressed. Moreover, the expression of 12 randomly selected transcripts was determined by real-time quantitative polymerase chain reaction to test the reliability of RNA-seq data. Based on the interaction between miRNAs and mRNAs, as well as lncRNAs/circRNAs and miRNAs, we constructed comprehensive lncRNA or circRNA-associated ceRNA networks in DIC mice. Moreover, we performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses for differentially expressed genes. In conclusion, these identified ceRNA interactions provide new insight into the underlying mechanism and may be crucial therapeutic targets of DIC.
Get full access to this article
View all access options for this article.
References
1.
AbbasN., PerbelliniF., and ThumT. (2020). Non-coding RNAs: emerging players in cardiomyocyte proliferation and cardiac regeneration. Basic Res Cardiol 115,52.
2.
AnY., FurberK.L., and JiS. (2017). Pseudogenes regulate parental gene expression via ceRNA network. J Cell Mol Med, 21, 185–192.
3.
AvagimyanA., KakturskiyL., Heshmat-GhahdarijaniK., PogosovaN., and SarrafzadeganN. (2021). Anthracycline associated disturbances of cardiovascular homeostasis. Curr Probl Cardiol 47,100909.
4.
AzizA.U.R., GengC., LiW., YuX., QinK.R., WangH., et al. (2019). Doxorubicin induces ER calcium release via Src in rat ovarian follicles. Toxicol Sci, 168, 171–178.
5.
BaoJ.L., and LinL. (2014). MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-kappaB pathway during acute viral myocarditis. Eur Rev Med Pharmacol Sci, 18, 2349–2356.
6.
CaloreM., LorenzonA., VitielloL., PoloniG., KhanM.A.F., BeffagnaG., et al. (2019). A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation. Cardiovasc Res, 115, 739–751.
7.
CardinaleD., ColomboA., BacchianiG., TedeschiI., MeroniC.A., VegliaF., et al. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131, 1981–1988.
8.
ChangK.T., ChengC.F., KingP.C., LiuS.Y., and WangG.S. (2017). CELF1 mediates connexin 43 mRNA degradation in dilated cardiomyopathy. Circ Res, 121, 1140–1152.
9.
ChenL., YanK.P., LiuX.C., WangW., LiC., LiM., et al. (2018). Valsartan regulates TGF-beta/Smads and TGF-beta/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure. Arch Pharm Res, 41, 101–109.
10.
ChengW., LiX.W., XiaoY.Q., and DuanS.B. (2019). Non-coding RNA-associated ceRNA networks in a new contrast-induced acute kidney injury rat model. Mol Ther Nucleic Acids, 17, 102–112.
11.
DengS., ZhaoQ., ZhenL., ZhangC., LiuC., WangG., et al. (2017). Neonatal heart-enriched miR-708 promotes proliferation and stress resistance of cardiomyocytes in rodents. Theranostics, 7, 1953–1965.
12.
EstellerM. (2011). Non-coding RNAs in human disease. Nat Rev Genet, 12, 861–874.
13.
GioffreS., RicciV., VavassoriC., RuggeriC., ChiesaM., AlfieriI., et al. (2019). Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity. Biomed Pharmacother, 110, 1–8.
14.
GiudiceJ., XiaZ., LiW., and CooperT.A. (2016). Neonatal cardiac dysfunction and transcriptome changes caused by the absence of Celf1. Sci Rep 6,35550.
15.
GuL., WangH., WangJ., GuoY., TangY., MaoY., et al. (2017). Reconstitution of HuR-inhibited CUGBP1 expression protects cardiomyocytes from acute myocardial infarction-induced injury. Antioxid Redox Signal, 27, 1013–1026.
16.
HadasY., VincekA.S., YoussefE., ZakM.M., ChepurkoE., SultanaN., et al. (2020). Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction. Circulation, 141, 916–930.
17.
HanD., WangY., WangY., DaiX., ZhouT., ChenJ., et al. (2020). The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a. Circ Res, 127, e108–e125.
18.
HanouskovaB., SkalaM., BrynychovaV., ZarybnickyT., SkarkovaV., KazimirovaP., et al. (2019). Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice-A comparison with doxorubicin. Biomed Pharmacother 115,108883.
19.
HydockD.S., WondersK.Y., SchneiderC.M., and HaywardR. (2009). Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res, 29, 4401–4407.
20.
JeyapalanZ., DengZ., ShatsevaT., FangL., HeC., and YangB.B. (2011). Expression of CD44 3'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res, 39, 3026–3041.
21.
LiC.Y., WangZ.K., ZhangJ.J., ZhaoX.Y., XuP., LiuX.Y., et al. (2019). Crosstalk of mRNA, miRNA, lncRNA, and circRNA and their regulatory pattern in pulmonary fibrosis. Mol Ther-Nucl Acids, 18, 204–218.
22.
LiJ., LiL., LiX., and WuS.Z. (2018). Long noncoding RNA LINC00339 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting MiR-484. Biochem Bioph Res Co, 503, 3038–3043.
23.
LingX., YaoD., KangL., ZhouJ., ZhouY., DongH., et al. (2017). Involment of RAS/ERK1/2 signaling and MEF2C in miR-155-3p inhibition-triggered cardiomyocyte differentiation of embryonic stem cell. Oncotarget, 8, 84403–84416.
24.
PakravanG., ForoughmandA.M., PeymaniM., GhaediK., HashemiM.S., HajjariM., et al. (2018). Downregulation of miR-130a, antagonized doxorubicin-induced cardiotoxicity via increasing the PPARgamma expression in mESCs-derived cardiac cells. Cell Death Dis, 9, 758.
25.
PollerW., DimmelerS., HeymansS., ZellerT., HaasJ., KarakasM., et al. (2018). Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J, 39, 2704–2716.
26.
RawatP.S., JaiswalA., KhuranaA., BhattiJ.S., and NavikU. (2021). Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 139,111708.
27.
RenuK., V G.A., P B.T., and ArunachalamS. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy—an update. Eur J Pharmacol, 818, 241–253.
28.
Rodriguez-MelendezR., and ZempleniJ. (2003). Regulation of gene expression by biotin (review). J Nutr Biochem, 14, 680–690.
29.
SalmenaL., PolisenoL., TayY., KatsL., and PandolfiP.P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell, 146, 353–358.
30.
ShabalalaS., MullerC.J.F., LouwJ., and JohnsonR. (2017). Polyphenols, autophagy and doxorubicin-induced cardiotoxicity. Life Sci, 180, 160–170.
31.
SlackF.J., and ChinnaiyanA.M. (2019). The role of non-coding RNAs in oncology. Cell, 179, 1033–1055.
32.
SmithL.A., CorneliusV.R., PlummerC.J., LevittG., VerrillM., CanneyP., et al. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10,337.
33.
SniderJ.M., TrayssacM., ClarkeC.J., SchwartzN., SniderA.J., ObeidL.M., et al. (2019). Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis. J Lipid Res, 60, 819–831.
34.
SongL., QiaoG., XuY., MaL., and JiangW. (2018). Role of non-coding RNAs in cardiotoxicity of chemotherapy. Surg Oncol, 27, 526–538.
35.
SunZ., TongG., MaN., LiJ., LiX., LiS., et al. (2013). NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury. Basic Res Cardiol 108,341.
36.
SwainS.M., WhaleyF.S., and EwerM.S. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97, 2869–2879.
37.
TayY., RinnJ., and PandolfiP.P. (2014). The multilayered complexity of ceRNA crosstalk and competition. Nature, 505, 344–352.
38.
TongZ., JiangB., WuY., LiuY., LiY., GaoM., et al. (2015). MiR-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting BTG2. Int J Mol Sci, 16, 14511–14525.
39.
TonyH., YuK., and QiutangZ. (2015). MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction. Oxid Med Cell Longev 2015,597032.
40.
VermaS.K., DeshmukhV., LiuP., NutterC.A., EspejoR., HungM.L., et al. (2013). Reactivation of fetal splicing programs in diabetic hearts is mediated by protein kinase C signaling. J Biol Chem, 288, 35372–35386.
41.
VisserG., SuormalaT., SmitG.P., ReijngoudD.J., Bink-BoelkensM.T., Niezen-KoningK.E., et al. (2000). 3-methylcrotonyl-CoA carboxylase deficiency in an infant with cardiomyopathy, in her brother with developmental delay and in their asymptomatic father. Eur J Pediatr, 159, 901–904.
42.
WangB., WangX., TongX., and ZhangY. (2020). Schisandrin B inhibits cell viability and migration, and induces cell apoptosis by circ_0009112/miR-708-5p axis through PI3K/AKT pathway in osteosarcoma. Front Genet 11,588670.
43.
WangG.S., KearneyD.L., De BiasiM., TaffetG., and CooperT.A. (2007). Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest, 117, 2802–2811.
44.
WangJ.X., ZhangX.J., FengC., SunT., WangK., WangY., et al. (2015). MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis 6,e1677.
45.
WangX., ChengZ., XuJ., FengM., ZhangH., ZhangL., et al. (2021). Circular RNA Arhgap12 modulates doxorubicin-induced cardiotoxicity by sponging miR-135a-5p. Life Sci 265,118788.
46.
WenningmannN., KnappM., AndeA., VaidyaT.R., and Ait-OudhiaS. (2019). Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol, 96, 219–232.
47.
XiaW., ChenH., XieC., and HouM. (2020). Long-noncoding RNA MALAT1 sponges microRNA-92a-3p to inhibit doxorubicin-induced cardiac senescence by targeting ATG4a. Aging (Albany NY), 12, 8241–8260.
48.
XieZ., XiaW., and HouM. (2018). Long intergenic noncoding RNAp21 mediates cardiac senescence via the Wnt/betacatenin signaling pathway in doxorubicin-induced cardiotoxicity. Mol Med Rep, 17, 2695–2704.
49.
YanH., LiY., WangC., ZhangY., LiuC., ZhouK., et al. (2017). Contrary microRNA expression pattern between fetal and adult cardiac remodeling: therapeutic value for heart failure. Cardiovasc Toxicol, 17, 267–276.
50.
ZhanJ., HuP., and WangY. (2020). lncRNA PVT1 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting the miR-187-3p/AGO1 axis. Mol Cell Probes 49,101490.
51.
ZhangD.X., MaD.Y., YaoZ.Q., FuC.Y., ShiY.X., WangQ.L., et al. (2016). ERK1/2/p53 and NF-κB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis. Eur Rev Med Pharmacol Sci, 20, 2435–2442.
52.
ZhangZ., YangB., HuangJ., LiW., YiP., YiM., et al. (2021). Identification of the protective effect of Polygonatum sibiricum polysaccharide on d-galactose-induced brain ageing in mice by the systematic characterization of a circular RNA-associated ceRNA network. Pharm Biol, 59, 347–366.
53.
ZhaoL., QiY., XuL., TaoX., HanX., YinL., et al. (2018). MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol, 15, 284–296.
54.
ZhaoZ., and QinX. (2020). MicroRNA-708 targeting ZNF549 regulates colon adenocarcinoma development through PI3K/AKt pathway. Sci Rep 10,16729.
55.
ZhengX., HuangH., LiuJ., LiM., LiuM., and LuoT. (2018). Propofol attenuates inflammatory response in LPS-activated microglia by regulating the miR-155/SOCS1 pathway. Inflammation, 41, 11–19.
56.
ZhouR.S., ZhangE.X., SunQ.F., YeZ.J., LiuJ.W., ZhouD.H., et al. (2019). Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue. BMC Cancer 19,779.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
